Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition
Novartis India Ltd · Investor Presentation · 04 Nov 2026, 1:14 am
Evonile Pharma Reports Q2 FY27 Financial Results and Business Model Transition Evonile Pharma transitioned to an independent domestic model, establishing 20+ CFAs and 2,000+ stockists. Q2 FY27 revenue from operations declined 38% YoY to ₹56.1 cr from ₹90.3 cr in Q2 FY26 due to the business model shift. Operating EBITDA was -₹31.8 cr with a net loss of ₹77.5 cr, impacted by ₹15.4 cr in one-off transition expenses and ₹68.3 cr in exceptional items from promotion rights termination. H1 FY27 revenue stood at ₹159.9 cr with a ₹45.3 cr net loss.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
